Cerebrospinal fluid levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in subacute sclerosing panencephalitis

Journal of Infection

Volumn 56, Issue 5, 2008, Pages 376-380

  Ichiyama, Takashi ^a   Matsushige, Takeshi ^a   Siba, Peter ^b   Suarkia, Dagwin ^b   Takasu, Toshiaki ^c   Miki, Kenji ^c   Furukawa, Susumu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebrospinal fluid; Matrix metalloproteinase 9; Subacute sclerosing panencephalitis; Tissue inhibitor of metalloproteinase 1

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADOLESCENT; ANTIBODY TITER; ARTICLE; BRAIN DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MALE; PAPUA NEW GUINEA; PATHOGENESIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SUBACUTE SCLEROSING PANENCEPHALITIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 9; PAPUA NEW GUINEA; SUBACUTE SCLEROSING PANENCEPHALITIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 43049136838     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.02.014     Document Type: Article

References (39)

1. Lucas K.M., Sanders R.C., Rongap A., Rongap T., Pinai S., and Alpers M.P. Subacute sclerosing panencephalitis (SSPE) in Papua New Guinea: a high incidence in young children. Epidemiol Infect 108 (1992) 547-553
2. Takasu T., Mgone J.M., Mgone C.S., Miki K., Komase K., Namae H., et al. A continuing high incidence of subacute sclerosing panencephalitis (SSPE) in the Eastern Highlands of Papua New Guinea. Epidemiol Infect 131 (2003) 887-898
3. CDC. Subacute sclerosing panencephalitis surveillance - United States. MMWR Morb Mortal Wkly Rep 31 (1982) 585-588
4. Dyken P.R. Subacute sclerosing panencephalitis. current status. Neurol Clin 3 (1985) 179-196
5. Editorial. SSPE in the developing world. Lancet 336 (1990) 600
6. Chandler S., Miller K.M., Clements J.M., Lury J., Corkill D., Anthony D.C., et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72 (1997) 155-161
7. Welgus H.G., Campbell E.J., Cury J.D., Eisen A.Z., Senior R.M., Wilhelm S.M., et al. Neutral metalloproteinases produced by human mononuclear phagocytes. enzyme profile, regulation, and expression during cellular development. J Clin Invest 186 (1990) 1496-1502
8. Chakraborti S., Mandal M., Das S., Mandal A., and Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253 (2003) 269-285
9. Leppert D., Waubant E., Galardy R., Bunnett N.W., and Hauser S.L. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 154 (1995) 4379-4389
10. Rosenberg G.A., Dencoff J.E., Correa Jr. N., Reiners M., and Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46 (1996) 1626-1632
11. Chandler S., Coates R., Gearing A., Lury J., Wells G., and Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 201 (1995) 223-226
12. Hartung H.P., and Kieseier B.C. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107 (2000) 140-147
13. Newman T.A., Woolley S.T., Hughes P.M., Sibson N.R., Anthony D.C., and Perry V.H. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124 (2001) 2203-2214
14. Murphy G., and Knäuper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?. Matrix Biol 15 (1997) 511-518
15. Lacraz S., Nicod L.P., Chicheportiche R., Welgus H.G., and Dayer J.M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96 (1995) 2304-2310
16. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53 (1999) 1397-1401
17. Rosenberg G.A. Matrix metalloproteinases biomarkers in multiple sclerosis. Lancet 365 (2005) 1291-1293
18. Ribatti D., Marimpietri D., Pastorino F., Brignole C., Nico B., Vacca A., et al. Angiogenesis in neuroblastoma. Ann N Y Acad Sci 1028 (2004) 133-142
19. Lee J.M., Yin K., Hsin I., Chen S., Fryer J.D., Holtzman D.M., et al. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci 229-230 (2005) 249-254
20. Ichiyama T., Kajimoto M., Suenaga N., Maeba S., Matsubara T., and Furukawa S. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. J Neuroimmunol 172 (2006) 182-186
21. Ichiyama T., Morishima T., Kajimoto M., Matsushige T., Matsubara T., and Furukawa S. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy. Pediatr Infect Dis J 26 (2007) 542-544
22. Suenaga N., Ichiyama T., Kubota M., Isumi H., Tohyama J., and Furukawa S. Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures. J Neurol Sci 266 (2008) 126-130
23. Ichiyama T., Siba P., Suarkia D., Takasu T., Miki K., Kira R., et al. Serum levels of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in subacute sclerosing panencephalitis. J Neurol Sci 252 (2007) 45-48
24. Jabbour J.T., Duenas D.A., and Modlin J. SSPE: clinical staging, course, and frequency, 1975. Arch Neurol 32 (1975) 493-494
25. Anlar B., Söylemezoǧlu F., Aysun S., Köse G., Belen D., and Yalaz K. Tissue inflammatory response in subacute sclerosing panencephalitis (SSPE). J Child Neurol 16 (2001) 895-900
26. Lukes A., Mun-Bryce S., Lukes M., and Rosenberg G.A. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 19 (1999) 267-284
27. Meli D.N., Christen S., and Leib S.L. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis 187 (2003) 1411-1415
28. Leib S.L., Kim Y.S., Chow L.L., Sheldon R.A., and Täuber M.G. Reactive oxygen intermediates contribute to necrotic and apoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J Clin Invest 98 (1996) 2632-2639
29. Leib S.L., Clements J.M., Lindberg R.L., Heimgartner C., Loeffler J.M., Pfister L.A., et al. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 124 (2001) 1734-1742
30. Leib S.L., Leppert D., Clements J., and Täuber M.G. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 68 (2000) 615-620
31. Solorzano C.C., Ksontini R., Pruitt J.H., Auffenberg T., Tannahill C., Galardy R.E., et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor α (TNF α) and abrogates endotoxin-induced lethality. Shock 7 (1997) 427-431
32. Rosenberg G.A., Estrada E.Y., Dencoff J.E., and Stetler-Stevenson W.G. Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 703 (1995) 151-155
33. Duncombe A.S., and Brenner M.K. Is circulating tumor necrosis factor bioactive?. N Engl J Med 319 (1988) 1227
34. Seckinger P., Issaz S., and Dayer J.M. A human inhibitor of tumor necrosis factor α. J Exp Med 167 (1988) 1511-1516
35. Engelmann H., Novick D., and Wallach D. Two tumor necrosis factor-binding proteins purified from human urine; evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265 (1990) 1531-1536
36. Ichiyama T., Hayashi T., and Furukawa S. Subacute sclerosing panencephalitis. Neurology 48 (1997) 1142-1143
37. Hofman F.M., Hinton D.R., Baemayr J., Weil M., and Merrill J.E. Lymphokines and immunoregulatory molecules in subacute sclerosing panencephalitis. Clin Immunol Immunopathol 58 (1991) 331-342
38. Nagano I., Nakamura S., Yoshioka M., Onodera J., Kogure K., and Itoyama Y. Expression of cytokines in brain lesions in subacute sclerosing panencephalitis. Neurology 44 (1994) 710-715
39. Liuzzi G.M., Trojano M., Fanelli M., Avolio C., Fasano A., Livrea P., et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 8 (2002) 222-228